Safety and immunogenicity of a meningococcal quadrivalent conjugate vaccine in five- to eight-year-old Saudi Arabian children previously vaccinated with two doses of a meningococcal quadrivalent polysaccharide vaccine

Clinical and Vaccine Immunology

Volumn 19, Issue 10, 2012, Pages 1561-1566

  Khalil, Mohamed ^a   Al Mazrou, Yagob ^a   Findlow, Helen ^b   Chadha, Helen ^b   Castells, Valerie Bosch ^c   Johnson, David R ^c   Borrow, Ray ^b,d  

^a MINISTRY OF HEALTH   (Saudi Arabia)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c SANOFI PASTEUR   (France)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; MENINGOCOCCUS VACCINE;

ANTIBODY TITER; ARTICLE; CHILD; CONTROLLED STUDY; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MALAISE; MULTICENTER STUDY; MYALGIA; NORMAL HUMAN; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; SAUDI ARABIA; SCHOOL CHILD; SERUM BACTERICIDAL ACTIVITY;

ANTIBODIES, BACTERIAL; CHILD; CHILD, PRESCHOOL; DIPHTHERIA TOXOID; HUMANS; IMMUNOGLOBULIN G; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; SAUDI ARABIA; VACCINES, CONJUGATE;

EID: 84867241039     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00260-12     Document Type: Article

References (21)

1. Al-Gahtani YM, el Bushra HE, al-Qarawi SM, al-Zubaidi AA, Fontaine RE. 1995. Epidemiological investigation of an outbreak of meningococcal meningitis in Makkah (Mecca), Saudi Arabia, 1992. Epidemiol. Infect. 115:399-409. (Pubitemid 26025314)
2. Al-Mazrou Y, et al. 2005. Serologic responses to ACYW135 polysaccharide meningococcal vaccine in Saudi children under 5 years of age. Infect. Immun. 73:2932-2939.
3. Al-Mazrou YY, et al. 2003. Disease burden and case management of bacterial meningitis among children under 5 years of age in Saudi Arabia. Saudi Med. J. 24:1300 -1307.
4. Al-Salman S, El Bushra HE. 1998. Meningitis in Makkah, January-April 1997. Saudi Epidemiol. Bull. 5:2-7.
5. Borrow R, Balmer P, Miller E. 2005. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine 23:2222-2227. (Pubitemid 40341456)
6. Borrow R, et al. 2001. Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children. J. Infect. Dis. 184:377-380. (Pubitemid 32662189)
7. Findlow H, et al. 2009. Investigation of different group A immunoassays following one dose of meningococcal group A conjugate vaccine or A/C polysaccharide vaccine in adults. Clin. Vaccine Immunol. 16:969 -977.
8. Gold R, Lepow ML, Goldschneider I, Draper TF, Gotschlich EC. 1979. Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. J. Infect. Dis. 140:690-697. (Pubitemid 10214192)
9. Hajjeh R, Lingappa JR. 2000. Meningococcal disease in the Kingdom of Saudi Arabia: an evaluation of disease surveillance and control after an outbreak of serogroup W-135. CDC Rep. 23:2000.
10. Jokhdar H, et al. 2004. Immunologic hyporesponsiveness to serogroup C but not serogroup A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia. Clin. Diagn. Lab. Immunol. 11:83- 88.
11. Khalil M, et al. 2005. Immunogenicity of meningococcal ACYW135 polysaccharide vaccine in Saudi children 5 to 9 years of age. Clin. Diagn. Lab. Immunol. 12:1251-1253. (Pubitemid 41475838)
12. Khalil MK, Borrow R. 2009. Serogroup B meningococcal disease during Hajj: preparing for the worst scenario. Travel Med. Infect. Dis. 7:231-234.
13. Lal G, Balmer P, Joseph H, Dawson M, Borrow R. 2004. Development and evaluation of a tetraplex flow cytometric assay for quantitation of serum antibodies to Neisseria meningitidis serogroups A, C, Y, and W-135. Clin. Diagn. Lab. Immunol. 11:272-279. (Pubitemid 38380806)
14. Leach A, et al. 1997. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J. Infect. Dis. 175:200-204. (Pubitemid 27020849)
15. Lingappa JR, et al. 2003. Serogroup W-135 meningococcal disease during the Hajj, 2000. Emerg. Infect. Dis. 9:665- 671.
16. MacDonald NE, Halperin SA, Law BJ, Danzig LE, Granoff DM. 2000. Can meningococcal C conjugate vaccine overcome immune hyporesponsiveness induced by previous administration of plain polysaccharide vaccine? JAMA 283:1826 -1827.
17. Maslanka SE, et al. 1997. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroupAandCserum bactericidal assays. Clin. Diagn. Lab. Immunol. 4:156 -167.
18. Memish ZA. 2002. Meningococcal disease and travel. Clin. Infect. Dis. 34:84 -90.
19. Ministry of Health, Kingdom of Saudi Arabia. 2009. Health services in Hajj season, 1429 (2008). Chapter 4. Ministry of Health, Riyadh, Saudi Arabia. http://www.moh.gov.sa/en/Ministry/Statistics/book/flash/1429/MOH-Report-1429. html.
20. Pichichero M, et al. 2005. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharidediphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children. Pediatr. Infect. Dis. J. 24:57- 62.
21. Sow S, et al. 2011. Immunogenicity, safety, and induction of immune memory of a new meningococcal group A conjugate vaccine in 1 to 29 year-old West Africans. N. Engl. J. Med. 364:2293-2304.